ADMA Biologics (NASDAQ:ADMA) Stock Price Breaks Below 200-Day Moving Average – Time to Sell?

ADMA Biologics Inc (NASDAQ:ADMA)’s share price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.93 and traded as low as $10.25. ADMA Biologics shares last traded at $10.48, with a volume of 13,368,485 shares changing hands.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus, while GAAP EPS was $0.22 and adjusted EPS was $0.23—both above estimates. GAAP net income rose 37% year over year to $49.9 million. ADMA Q3 results and business update
• Positive Sentiment: ASCENIV revenue increased 31% year over year to $124.7 million. Gross margin expanded by about 1,450 basis points to 71%, and adjusted EBITDA grew 32% to $77.3 million, indicating improving profitability and operating leverage. ADMA Q3 results and business update
• Positive Sentiment: The company increased its adjusted earnings outlook, cited encouraging regulatory feedback for SG-001, and highlighted share repurchases and evidence supporting ASCENIV’s commercial position. ADMA Q3 results and business update
• Neutral Sentiment: ADMA reiterated its FY2026 revenue guidance rather than raising it. Revenue grew 5% year over year, a more modest rate than ASCENIV’s growth; these factors may have tempered the upbeat earnings report, though the provided articles do not establish why the stock fell. ADMA Q3 results and business update

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ADMA. Mizuho cut their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Price Performance

The company’s 50-day simple moving average is $10.07 and its 200 day simple moving average is $10.93. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of 14.97 and a beta of 0.65.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The firm had revenue of $141.10 million during the quarter, compared to analyst estimates of $138.11 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.15 EPS. Equities research analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of ADMA Biologics during the second quarter worth $321,037,000. Dimensional Fund Advisors LP increased its stake in shares of ADMA Biologics by 3.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company’s stock valued at $45,101,000 after buying an additional 169,843 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after buying an additional 2,071,338 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of ADMA Biologics in the second quarter valued at about $19,753,141. Finally, Ranger Investment Management L.P. acquired a new position in ADMA Biologics during the 2nd quarter worth about $17,706,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.